Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
HUM Stock Summary
Top 10 Correlated ETFs
HUM
In the News

Humana: Buy This Amazing Wealth Compounder Now, You'll Be Glad You Did
Humana's adjusted diluted EPS and free cash flow payout ratios make the dividend very secure. The managed care company's revenue and adjusted diluted EPS both surged in the first half of 2023. Humana's interest coverage ratio of over 13 is part of why it earns investment-grade credit ratings from the major rating agencies.

Buy the Dip: 3 Healthcare Stocks to Snag Now for Supercharged Gains
In the ever-evolving landscape of investing, the spotlight is on the top healthcare stocks to buy on the dip. The healthcare sector is highly known for its robust resilience and incredible growth potential.

The 3 Most Undervalued Healthcare Stocks to Buy in September 2023
Healthcare is a sector that has underperformed the broader stock market this year. The S&P 500 Health Care Sector Index is down over 2.50% year-to-date versus a 17% gain in the benchmark S&P 500 index.

Here's Why Investors Should Hold Humana (HUM) in Portfolio
Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.

Humana (HUM) to Provide In-home Care With Primary Care Anywhere
Humana (HUM) enhances its CenterWell brand with the launch of Primary Care Anywhere.

Why Humana (HUM) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

A Quality Executive Compensation Plan Lowers The Risk Of Investing In Humana
Humana (HUM) is the featured stock in August's Exec Comp Aligned with ROIC Model Portfolio.

5 HMO Stocks to Watch Amid Growing Premiums & Membership
Expanding customer base, contract wins and a rapidly growing aging U.S. population will likely drive the performances of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry trends.

Humana (HUM) to Bring Enhanced Kidney Care to MA Members
Humana (HUM) makes Interwell's extensive resources available to its MA members grappling with CKD and ESKD, and hence bring about better health outcomes for them.

Humana Inc. to Present at the Wells Fargo 2023 Healthcare Conference
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) announced today that Bruce D. Broussard, President and Chief Executive Officer, and Susan M. Diamond, Chief Financial Officer, will make a presentation to investors at the Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 8:00 a.m. Eastern time. A live audio webcast of the presentation will be available via Humana's Investor Relations page at humana.com. The company suggests webcast participants sign on approximately.
HUM Financial details
HUM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 413.95 | 484.04 | 583.63 | 645.47 | 721.67 | |
Net income per share | 12.24 | 20.19 | 25.47 | 22.79 | 21.8 | |
Operating cash flow per share | 15.81 | 39.42 | 42.66 | 17.58 | 35.64 | |
Free cash flow per share | 11.35 | 33.93 | 35.36 | 7.35 | 26.94 | |
Cash per share | 89.97 | 112.09 | 130.31 | 128.89 | 147.19 | |
Book value per share | 73.91 | 89.79 | 103.84 | 124.95 | 118.98 | |
Tangible book value per share | 43.78 | 59.17 | 67.72 | 18.43 | 34.68 | |
Share holders equity per share | 73.91 | 89.79 | 103.84 | 124.95 | 118.98 | |
Interest debt per share | 46.97 | 45.75 | 54.94 | 102.15 | 91.89 | |
Market cap | 39.39B | 49.13B | 54.24B | 59.69B | 65.91B | |
Enterprise value | 43.28B | 50.97B | 56.54B | 69.12B | 72.28B | |
P/E ratio | 23.4 | 18.15 | 16.11 | 20.35 | 23.49 | |
Price to sales ratio | 0.69 | 0.76 | 0.7 | 0.72 | 0.71 | |
POCF ratio | 18.13 | 9.3 | 9.62 | 26.39 | 14.37 | |
PFCF ratio | 25.23 | 10.8 | 11.6 | 63.1 | 19.01 | |
P/B Ratio | 3.88 | 4.08 | 3.95 | 3.71 | 4.3 | |
PTB ratio | 3.88 | 4.08 | 3.95 | 3.71 | 4.3 | |
EV to sales | 0.76 | 0.79 | 0.73 | 0.83 | 0.78 | |
Enterprise value over EBITDA | 15.32 | 12.6 | 10.69 | 16.73 | 15.01 | |
EV to operating cash flow | 19.92 | 9.65 | 10.03 | 30.56 | 15.76 | |
EV to free cash flow | 27.73 | 11.21 | 12.1 | 73.06 | 20.85 | |
Earnings yield | 0.04 | 0.06 | 0.06 | 0.05 | 0.04 | |
Free cash flow yield | 0.04 | 0.09 | 0.09 | 0.02 | 0.05 | |
Debt to equity | 0.61 | 0.49 | 0.51 | 0.8 | 0.75 | |
Debt to assets | 0.25 | 0.2 | 0.2 | 0.29 | 0.27 | |
Net debt to EBITDA | 1.38 | 0.45 | 0.44 | 2.28 | 1.32 | |
Current ratio | 1.34 | 1.48 | 1.4 | 1.22 | 1.52 | |
Interest coverage | 10.51 | 14.34 | 16.52 | 10.48 | 9.9 | |
Income quality | 1.29 | 1.95 | 1.67 | 0.77 | 1.64 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.16 | 0.11 | 0.1 | 0.12 | 0.14 | |
Sales general and administrative to revenue | 0.13 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.16 | 0.14 | 0.13 | 0.25 | 0.21 | |
Capex to operating cash flow | -0.28 | -0.14 | -0.17 | -0.58 | -0.24 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | |
Capex to depreciation | -1.15 | -1.28 | -1.56 | -1.85 | -1.33 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 142.67 | 201.98 | 243.94 | 253.14 | 241.6 | |
ROIC | 0.11 | 0.15 | 0.16 | 0.1 | 0.12 | |
Return on tangible assets | 0.08 | 0.11 | 0.11 | 0.09 | 0.08 | |
Graham Net | -28.39 | -23.29 | -43.86 | -105.22 | -58.18 | |
Working capital | 3.37B | 5.19B | 5.29B | 3.33B | 9.01B | |
Tangible asset value | 6.02B | 8.11B | 9.28B | 5.01B | 6.23B | |
Net current asset value | -1.87B | -955M | -2.88B | -9.84B | -1.5B | |
Invested capital | 0.61 | 0.49 | 0.51 | 0.8 | 0.75 | |
Average receivables | 934.5M | 1.04B | 1.1B | 1.48B | 1.74B | |
Average payables | 9.9B | 9.06B | 11.06B | 12.48B | 13.65B | |
Average inventory | -1.78B | -3.69B | -4.54B | -5.88B | -3.25B | |
Days sales outstanding | 6.51 | 5.94 | 5.38 | 7.97 | 6.58 | |
Days payables outstanding | 395.22 | 492.73 | 441.4 | 461.43 | 417.74 | |
Days of inventory on hand | -172.87 | -188.21 | -191.58 | -234.16 | 0 | |
Receivables turnover | 56.07 | 61.45 | 67.8 | 45.79 | 55.48 | |
Payables turnover | 0.92 | 0.74 | 0.83 | 0.79 | 0.87 | |
Inventory turnover | -2.11 | -1.94 | -1.91 | -1.56 | 0 | |
ROE | 0.17 | 0.22 | 0.25 | 0.18 | 0.18 | |
Capex per share | -4.45 | -5.49 | -7.29 | -10.23 | -8.7 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 187.02 | 180.13 | 178.59 | 213.93 | 214.71 | |
Net income per share | 5.5 | 9.44 | -0.1 | 9.91 | 7.7 | |
Operating cash flow per share | 7.58 | 66.78 | -40.81 | 53.49 | 25.49 | |
Free cash flow per share | 5.37 | 64.51 | -42.86 | 51.71 | 23.38 | |
Cash per share | 143.77 | 210.8 | 150.76 | 229.33 | 252.58 | |
Book value per share | 122.43 | 128.42 | 121.86 | 132.61 | 135.13 | |
Tangible book value per share | 31.43 | 42.85 | 35.52 | 58.51 | 59.02 | |
Share holders equity per share | 122.43 | 128.42 | 121.86 | 132.61 | 135.13 | |
Interest debt per share | 105.3 | 86.4 | 91.78 | 97.03 | 98.91 | |
Market cap | 59.22B | 61.41B | 64.35B | 60.68B | 55.7B | |
Enterprise value | 67.29B | 58.69B | 70.72B | 58.97B | 51.69B | |
P/E ratio | 21.27 | 12.85 | -1.24K | 12.24 | 14.52 | |
Price to sales ratio | 2.5 | 2.69 | 2.87 | 2.27 | 2.08 | |
POCF ratio | 61.75 | 7.27 | -12.55 | 9.08 | 17.54 | |
PFCF ratio | 87.09 | 7.52 | -11.95 | 9.39 | 19.13 | |
P/B Ratio | 3.82 | 3.78 | 4.2 | 3.66 | 3.31 | |
PTB ratio | 3.82 | 3.78 | 4.2 | 3.66 | 3.31 | |
EV to sales | 2.84 | 2.57 | 3.15 | 2.2 | 1.93 | |
Enterprise value over EBITDA | 46.96 | 36.27 | 280.62 | 31.08 | 33.01 | |
EV to operating cash flow | 70.17 | 6.94 | -13.79 | 8.82 | 16.27 | |
EV to free cash flow | 98.96 | 7.19 | -13.13 | 9.12 | 17.75 | |
Earnings yield | 0.01 | 0.02 | 0 | 0.02 | 0.02 | |
Free cash flow yield | 0.01 | 0.13 | -0.08 | 0.11 | 0.05 | |
Debt to equity | 0.85 | 0.67 | 0.75 | 0.72 | 0.72 | |
Debt to assets | 0.28 | 0.21 | 0.27 | 0.22 | 0.22 | |
Net debt to EBITDA | 5.63 | -1.68 | 25.25 | -0.91 | -2.56 | |
Current ratio | 1.57 | 1.49 | 1.52 | 1.39 | 1.37 | |
Interest coverage | 12.12 | 13.76 | 0.32 | 14.86 | 11.97 | |
Income quality | 1.38 | 7.09 | 284.83 | 5.4 | 3.32 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.14 | 0.08 | -7.77 | 0.08 | 0.12 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.25 | 0.21 | 0.21 | 0.17 | 0.17 | |
Capex to operating cash flow | -0.29 | -0.03 | 0.05 | -0.03 | -0.08 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
Capex to depreciation | -1.33 | -1.35 | -1.19 | -1.02 | -1.17 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 123.1 | 165.16 | 16.84 | 171.97 | 152.99 | |
ROIC | 0.03 | 0.05 | 0 | 0.05 | 0.04 | |
Return on tangible assets | 0.02 | 0.03 | 0 | 0.03 | 0.02 | |
Graham Net | -83.73 | -125.08 | -59.59 | -57.16 | -56.41 | |
Working capital | 9.85B | 9.25B | 9.01B | 10.59B | 10.48B | |
Tangible asset value | 3.98B | 5.42B | 6.23B | 7.31B | 7.35B | |
Net current asset value | -4.09B | -6.16B | -1.5B | -610M | -805M | |
Invested capital | 0.85 | 0.67 | 0.75 | 0.72 | 0.72 | |
Average receivables | 3.27B | 2.49B | 1.64B | 2.39B | 2.27B | |
Average payables | 15.34B | 15.72B | 15.25B | 15.98B | 17.94B | |
Average inventory | -2.86B | -9.27B | -9.27B | 0 | 0 | |
Days sales outstanding | 12.81 | 6.35 | 6.71 | 10.46 | 4.81 | |
Days payables outstanding | 437.86 | 470.52 | 103.01 | 527.16 | 532.94 | |
Days of inventory on hand | 0 | -545.23 | 0 | 0 | 0 | |
Receivables turnover | 7.02 | 14.17 | 13.4 | 8.61 | 18.72 | |
Payables turnover | 0.21 | 0.19 | 0.87 | 0.17 | 0.17 | |
Inventory turnover | 0 | -0.17 | 0 | 0 | 0 | |
ROE | 0.04 | 0.07 | 0 | 0.07 | 0.06 | |
Capex per share | -2.21 | -2.28 | -2.05 | -1.78 | -2.12 |
HUM Frequently Asked Questions
What is Humana Inc. stock symbol ?
Humana Inc. is a US stock , located in Louisville of Ky and trading under the symbol HUM
Is Humana Inc. buy or a sell ?
34 stock analysts have 34 predictions with a medium analyst target price of $533.21. The lowest prediction is $450 and the highest is $652
What is HUM stock prediction ?
What is Humana Inc. stock quote today ?
Humana Inc. stock price is $495.36 today.
Is Humana Inc. stock public?
Yes, Humana Inc. is a publicly traded company.